117 related articles for article (PubMed ID: 38527651)
1. Prognostic value of KRAS G12V mutation in lung adenocarcinoma stratified by stages and radiological features.
Zhu W; Han H; Ma Z; Cao H; Yan Y; Zhao Y; Deng C; Xu H; Fu F; Fan F; Zhang Y; Chen H
J Thorac Cardiovasc Surg; 2024 Mar; ():. PubMed ID: 38527651
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.
Cao H; Ma Z; Li Y; Zhang Y; Chen H
J Thorac Cardiovasc Surg; 2023 Dec; 166(6):e479-e499. PubMed ID: 37142051
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
[TBL] [Abstract][Full Text] [Related]
5.
Jones GD; Caso R; Tan KS; Mastrogiacomo B; Sanchez-Vega F; Liu Y; Connolly JG; Murciano-Goroff YR; Bott MJ; Adusumilli PS; Molena D; Rocco G; Rusch VW; Sihag S; Misale S; Yaeger R; Drilon A; Arbour KC; Riely GJ; Rosen N; Lito P; Zhang H; Lyden DC; Rudin CM; Jones DR; Li BT; Isbell JM
Clin Cancer Res; 2021 May; 27(9):2604-2612. PubMed ID: 33593884
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With
Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY
JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991
[TBL] [Abstract][Full Text] [Related]
8. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
9. Molecular Signatures of
Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
[TBL] [Abstract][Full Text] [Related]
10. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
[TBL] [Abstract][Full Text] [Related]
11. Association of the KRAS genotype and clinicopathologic findings of resected non-small-cell lung cancer: A pooled analysis of 179 patients.
Masago K; Kuroda H; Sasaki E; Fujita S; Shinohara S; Sugita Y; Takahashi Y; Matsushita H
Cancer Genet; 2022 Nov; 268-269():64-74. PubMed ID: 36179532
[TBL] [Abstract][Full Text] [Related]
12. Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.
Raparia K; Villa C; Raj R; Cagle PT
Arch Pathol Lab Med; 2015 Feb; 139(2):189-93. PubMed ID: 24694341
[TBL] [Abstract][Full Text] [Related]
13. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
14. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
[TBL] [Abstract][Full Text] [Related]
16. KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma.
Gallina FT; Marinelli D; Melis E; Forcella D; Taje R; Buglioni S; Visca P; Torchia A; Cecere FL; Botticelli A; Santini D; Ciliberto G; Cappuzzo F; Facciolo F
Lung Cancer; 2023 Jul; 181():107254. PubMed ID: 37253296
[TBL] [Abstract][Full Text] [Related]
17. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
[TBL] [Abstract][Full Text] [Related]
18. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.
Tamiya Y; Matsumoto S; Zenke Y; Yoh K; Ikeda T; Shibata Y; Kato T; Nishino K; Nakamura A; Furuya N; Miyamoto S; Kuyama S; Nomura S; Ikeno T; Udagawa H; Sugiyama E; Nosaki K; Izumi H; Sakai T; Hashimoto N; Goto K
Lung Cancer; 2023 Feb; 176():103-111. PubMed ID: 36634571
[TBL] [Abstract][Full Text] [Related]
19. Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras
Kumar G; Madka V; Singh A; Farooqui M; Stratton N; Lightfoot S; Mohammed A; Rao CV
Neoplasia; 2021 Jun; 23(6):574-583. PubMed ID: 34091121
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
Lee B; Lee T; Lee SH; Choi YL; Han J
Oncotarget; 2016 Apr; 7(17):23874-84. PubMed ID: 26992209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
